[VIRTUAL] Camidanlumab Tesirine Efficacy and Safety in an Open-label, Multicenter, Phase 2 Study of Patients (pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

camidanlumab tesirine (ADCT-301) - Genmab, ADC Therapeutics

Adcetris (brentuximab vedotin) - Seagen, Takeda

https://onlinelibrary.wiley.com/doi/10.1002/hon.2879

P. L. Zinzani; C. Carlo-Stella; M. Hamadani; A. F. Herrera; S. M. Ansell; J. Radford; K. Maddocks; J. Kline; K. J. Savage; N. L. Bartlett; P. F. Caimi; Y. Negievich; H. G. Cruz; L. Wang; J. Wuerthner; G. P. Collins

May 8, 2021